Cancer is a disease of tissues and not only of tumour cells. Therefore, treating the tissue rather than individual cancer cells is a paradigm-shifting approach to cancer therapy and substantially improves current cancer treatments.
Similar to normal cells, cancer cells depend on signals and support from their surrounding environment for survival, growth and resistance to therapies.
These signals derive from so-called stromal cells, which are mesenchymal cells in the tumour microenvironment. We are a group of pioneers committed to the development of novel anti-stromal therapies to treat cancer.
Stroma Biosciences has shown for the first time that targeting the tumour microenvironment is feasible and substantially improves current therapies for patients for which no curative treatments are available.
Who we are
Pursuing a pioneering approach to treat cancer
Be the world-leading biopharma company developing stroma therapies to tackle cancer by cutting the lifeline support of stroma for cancer cells.
To treat cancer as a tissue, thereby transforming palliative into curative treatments.
Commitment to improve cancer therapies. We at Stroma Biosciences have devoted our careers to understand the origins of cancer to improve patients’ wellbeing.
Quality: We are a group of scientists and oncologists with more than 130 years’ cumulative experience in treating cancer patients, development of novel drugs and advanced cancer research. Our new treatments are developed under the highest scientific and clinical standards with an established pathway to clinical trials.
Collaborations: We believe that communication and collaborations are the route to success. Stroma Biosciences is embedded in the biomedical community in Cambridge, UK, with long standing collaborations with world-leading scientists and entrepreneurs.
Alongside our in-house programs we are actively seeking partners who wish to work with us and exploit our proprietary platform to develop novel therapies
WHY STROMA BIOSCIENCES
While recent advances in cancer therapy are aimed at improving therapies by harnessing immune cells, targeting the stromal compartment as anti-cancer therapy is a largely unexplored field. More than 15 years ago, we at Stroma Biosciences recognised the enormous potential of treating stromal cells to improve cancer therapies.
Historically, research has mainly been focused on cancer cells, under appreciating that cancer is a disease of tissues rather than of individual cells.
Our experience in the tumour microenvironment field, extending for more than a decade, puts us at the forefront of stroma research to develop novel therapies. Our proprietary stroma-focused platform identifies and enables validation of novel targets.
A paradigm shifting approach to cancer therapy
We have deciphered critical molecular mechanisms underlying stroma support of tumour cells and demonstrated that interference with the stroma-tumour communication substantially improves therapies, potentially eradicating cancer cells in vivo.
This paradigm-shifting approach to cancer therapy has already led to a phase II clinical trial, which will for the first time demonstrate the clinical potential of stroma therapies.
Stroma Biosciences co-founders have been accepted as the cover story in Science Translational Medicine for their work on the tumour microenvironment. The research found that treating the normal cells near to the cancer cells with small molecule inhibitors...
If you would like to know more about Stroma Biosciences, or would like to discuss partnership or investment please contact us.